Cargando…

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas....

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombo, Anna, Giuffrè, Mauro, Crocè, Lory Saveria, Venturini, Sergio, Sablich, Renato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928/ https://www.ncbi.nlm.nih.gov/pubmed/33946817 http://dx.doi.org/10.3390/pathogens10050535

Ejemplares similares

Childbearing and Delivery in Women With Ulcerative Colitis and Ileostomy or Ileal Pouch-Anal Anastomosis
por: Campigotto, Michele, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis
por: Singh, Jatinderpal, et al.
Publicado: (2016)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Spontaneous porto‐femoral shunting in long‐standing portal hypertension
por: Giuffrè, Mauro, et al.
Publicado: (2020)

Incisional hernia by liver cysts
por: Giuffrè, Mauro, et al.
Publicado: (2022)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

The Importance of Transaminases Flare in Liver Elastography: Characterization of the Probability of Liver Fibrosis Overestimation by Hepatitis C Virus-Induced Cytolysis
por: Giuffrè, Mauro, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia
por: Moretti, Rita, et al.
Publicado: (2022)

Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis
por: Fusaro, Lisa, et al.
Publicado: (2023)

Disseminated tuberculosis following negative QuantiFERON-TB gold tests during infliximab therapy: Implications for screening of hidradenitis suppurativa
por: Ntiri, Michel, et al.
Publicado: (2022)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature
por: Campigotto, Michele, et al.
Publicado: (2020)

Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients
por: Pascut, Devis, et al.
Publicado: (2020)

Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature
por: Giuffrè, Mauro, et al.
Publicado: (2021)

Diverticular Disease and Rifaximin: An Evidence-Based Review
por: Piccin, Anna, et al.
Publicado: (2023)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon γ Release Assay (IGRA)-Based QuantiFERON Gold Test
por: Parita, Soni, et al.
Publicado: (2017)

Pediatric ulcerative colitis: current treatment approaches including role of infliximab
por: Bradley, Gia M, et al.
Publicado: (2012)

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
por: Chaudhary, Mohammad A., et al.
Publicado: (2012)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis
por: Nishida, Yu, et al.
Publicado: (2017)

Disseminated Nocardiosis Associated with Treatment with Infliximab in a Patient with Ulcerative Colitis
por: Garner, Orlando, et al.
Publicado: (2017)

Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
por: Liu, Yi-Juan, et al.
Publicado: (2018)

Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report
por: Gîlcă, Georgiana-Emmanuela, et al.
Publicado: (2017)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
por: Viscido, Angelo, et al.
Publicado: (2019)

Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
por: Jia, Xuemei, et al.
Publicado: (2020)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report
por: Huang, Bin-Bin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jo6adc3cjee17cl4hrs6l09nva